SCHEDULE 13G/A: BlackRock Discloses 1.0% Stake in Lineage Cell Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.0% beneficial ownership stake in Lineage Cell Therapeutics Inc., totaling 2,234,545 common shares.
Summary
- BlackRock, Inc. reported beneficial ownership of 2,234,545 shares of Lineage Cell Therapeutics Inc. common stock.
- This represents a 1.0% stake in the class of securities.
- BlackRock holds sole voting power and sole dispositive power over all 2,234,545 shares.
- The filing indicates that BlackRock's interest is less than 5% of the total outstanding common shares, and no single person's interest within BlackRock's holdings exceeds 5%.
- A contradiction exists in Exhibit 99, which states that "BlackRock Institutional Trust Company, National Association *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G," despite the main filing reporting 1.0%.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of passive beneficial ownership by a large institutional investor, with no explicit positive or negative implications for the issuer's performance. A minor contradiction regarding the 5% ownership threshold is noted.
Positives
- Disclosure of a 1.0% beneficial ownership by BlackRock, Inc., a major institutional investor, indicates continued institutional interest in Lineage Cell Therapeutics Inc.
Negatives
- A contradiction exists between the main filing, which states BlackRock's beneficial ownership is 1.0% and less than 5% of the class, and Exhibit 99, which indicates a subsidiary (BlackRock Institutional Trust Company, National Association) beneficially owns "5% or greater" of the outstanding shares. This discrepancy could lead to confusion regarding the actual reported stake by the BlackRock entity.
Risks
- The reported beneficial ownership is passive, meaning BlackRock, Inc. acquired and holds the securities in the ordinary course of business and not for the purpose of changing or influencing control of Lineage Cell Therapeutics Inc.
Future Outlook
NA
Management Comments
- BlackRock, Inc. certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. executed a new Power of Attorney on January 21, 2025, authorizing specific individuals to execute and file documents related to ownership or control-person reporting requirements, including SEC filings like Schedules 13D and 13G. This new Power of Attorney expressly revokes a previous one dated April 30, 2023. | 01/21/2025 | Streamlines the process for BlackRock to comply with various ownership and control-person reporting requirements for its subsidiaries and affiliates. |
Stakeholder Impact
- Shareholders are informed of the beneficial ownership stake held by BlackRock, Inc., providing transparency regarding institutional holdings.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previously revoked Power of Attorney for BlackRock, Inc. |
| 01/21/2025 | Date of execution for the new Power of Attorney for BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 07/17/2025 | Date of signature for the Schedule 13G filing by Spencer Fleming, Managing Director of BlackRock, Inc. |
Keywords
BlackRock, Lineage Cell Therapeutics Inc., Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.